Idera Pharmaceuticals, Inc. (IDRA): Mark J Casey , Senior VP & General Counsel of Idera Pharmaceuticals, Inc. purchased 34,450 shares on May 12, 2016. The Insider buying transaction was reported by the company on May 13, 2016 to the Securities and Exchange Commission. The shares were purchased at $1.44 per share for a total value of $49,608.00 , the company said in a SEC Form 4 Filing.
Other Insider transactions have been reported by the company according to SEC Form 4, on Mar 17, 2016, Vincent Milano (CEO) purchased 40,000 shares at $1.97 per share price.
Idera Pharmaceuticals Inc: On Tuesday, May 10, 2016 heightened volatility was witnessed in Idera Pharmaceuticals Inc which led to swings in the share price. The shares opened for trading at $1.36 and hit $1.42 on the upside , eventually ending the session at $1.42, with a gain of 2.16% or 0.03 points. The heightened volatility saw the trading volume jump to 25,90,228 shares. The 52-week high of the share price is $4.42 and the company has a market cap of $172 M . The 52-week low of the share price is at $1.19.
Idera Pharmaceuticals Inc. is a clinical-stage biopharmaceutical company focused on the discovery development and commercialization of therapeutics for oncology and rare diseases. The Company uses two drug discovery technology platforms to design and develop drug candidates. Using its Toll-like receptor (TLR) targeting technology the Company designs synthetic oligonucleotide-based drug candidates to act by modulating the activity of specific TLRs. Using its gene silencing oligonucleotide (GSO) technology the Company is developing GSOs to turn off the messenger RNA (mRNA) associated with disease causing genes. The Company’s drug candidates include IMO-8400 for Waldenstrom’s macroglobulinemia and diffuse large B-Cell lymphoma; IMO-2055/IMO-2125 for immune-oncology; IMO-8400 for dermatomyositis and Duchenne Muscular Dystrophy (DMD) and IMO-9200 for selected autoimmune disease.